By George Ongkojoyo 
The challenge of treating pancreatic ductal adenocarcinoma (PDAC) has long been defined by the tumor’s ability to shield itself from the human immune system, creating a biological fortress that renders traditional immunotherapies largely ineffective. While checkpoint inhibitors and other immune-boosting treatments have revolutionized the management of melanoma and lung cancer, pancreatic cancer remains notoriously resistant, primarily due to its "cold" tumor microenvironment. This environment is characterized by a dense, fibrous stroma and low oxygen levels that prevent cancer-fighting T cells from infiltrating the site of the disease. However, researchers at the University of Chicago have recently unveiled a breakthrough approach that leverages the unique properties of anaerobic bacteria to breach these defenses. By engineering a specific strain of probiotic bacteria to act as a localized drug factory, the team has demonstrated a new method to stimulate a potent immune response directly within the heart of pancreatic tumors.
In a study published in the journal Science Advances, the interdisciplinary team detailed the development of BifidoSumIL-2, a genetically modified version of Bifidobacterium longum. This bacterium, commonly found in the human gut and frequently used in commercial probiotics like yogurt, was redesigned to carry a therapeutic payload—a specialized version of the immune-signaling molecule interleukin-2 (IL-2). By utilizing the bacteria’s natural preference for low-oxygen environments, the researchers were able to concentrate the treatment within the tumor while sparing healthy tissues, effectively turning the tumor’s own hostile conditions into a gateway for therapy.
The Obstacle of the Cold Tumor Microenvironment
Pancreatic cancer is currently one of the deadliest forms of the disease, with a five-year survival rate that hovers around 13%. The primary reason for this high mortality rate is that the disease is often diagnosed at an advanced stage and is remarkably adept at evading the immune system. In many other cancers, the immune system recognizes the tumor as a threat and sends T cells to attack it; these are known as "hot" tumors. Pancreatic tumors, conversely, are "cold." They are surrounded by a thick layer of protective tissue and are characterized by hypoxia, or extremely low oxygen levels. This environment not only physical blocks T cells but also suppresses their activity, making it nearly impossible for the body to mount a natural defense.
For decades, clinicians have attempted to use IL-2 to jumpstart the immune system in cancer patients. IL-2 is a cytokine that promotes the proliferation and activation of T cells. However, systemic administration of IL-2 has been fraught with danger. High doses are required to reach the tumor, which often leads to severe side effects such as vascular leak syndrome, where fluid leaks from blood vessels into surrounding tissues, causing organ failure. Furthermore, standard IL-2 can inadvertently stimulate regulatory T cells (Tregs), which actually suppress the immune response, potentially aiding the tumor’s growth rather than hindering it.
Engineering a Precision Biological Delivery System
To solve the dual problem of delivery and toxicity, the University of Chicago team, led by Ralph Weichselbaum, MD, and Mark Mimee, PhD, turned to synthetic biology. They began with Bifidobacterium longum, an "obligate anaerobe." Unlike many bacteria that can survive in various environments, Bifidobacterium can only grow where oxygen is absent. Because healthy human tissues are well-oxygenated, the bacteria are naturally cleared by the body’s systems. However, the hypoxic core of a solid tumor provides the perfect sanctuary for these bacteria to thrive and multiply.
The researchers engineered the bacteria to produce "SumIL-2," a modified form of interleukin-2. This engineered molecule was designed with a specific goal: to maximize the activation of cancer-fighting CD8+ T cells while minimizing the activation of the immunosuppressive regulatory T cells. By placing the instructions for SumIL-2 inside the Bifidobacterium, the team created a delivery vehicle that remains dormant until it reaches the low-oxygen environment of the pancreatic tumor. Once settled, the bacteria begin to produce and secrete the SumIL-2 payload directly into the tumor microenvironment.
"A big unmet medical need has been pancreatic cancer, and so that was going to be our mountain to climb," said Dr. Weichselbaum, the Daniel K. Ludwig Distinguished Service Professor and Chair of Radiation and Cellular Oncology at the University of Chicago. The strategy represents a shift from systemic drug delivery to a localized, "living" medicine approach.
Preclinical Data and Synergistic Effects
The efficacy of BifidoSumIL-2 was tested in rigorous animal models of pancreatic cancer. The data revealed that the engineered bacteria selectively colonized the tumors, with little to no presence found in the lungs, liver, or spleen of the subjects. This localization resulted in a significant increase in the concentration of CD8+ T cells within the tumor, effectively "turning up the heat" on the previously cold microenvironment.
The study found that while BifidoSumIL-2 was effective as a standalone treatment, slowing tumor growth and extending survival, its true potential was realized when used in combination with existing therapies. When paired with radiation therapy, the bacterial treatment showed a synergistic effect, as radiation can help break down the tumor’s physical barriers, allowing the bacteria and the stimulated T cells better access. Similarly, combining the probiotic therapy with chemotherapy or anti-PD-L1 immunotherapy produced results that far exceeded the efficacy of any single treatment.
"This combination potential is one of the study’s most important findings," Weichselbaum noted. "BifidoSumIL-2 not only works by itself—it works with radiotherapy, chemotherapy, and immunotherapy." This versatility is crucial for pancreatic cancer, where multi-modal treatment plans are the standard of care.
Interdisciplinary Collaboration and the "Bugs as Drugs" Movement
The development of BifidoSumIL-2 was not the work of a single department but rather a "highly interdisciplinary effort," according to Mark Mimee, Assistant Professor of Microbiology. The project required the integration of microbiology to select and manage the bacteria, synthetic biology to engineer the IL-2 payload, and oncology and immunology to test the therapeutic outcomes.
The challenges were significant. Bifidobacterium is notoriously difficult to manipulate genetically compared to common laboratory bacteria like E. coli. It grows slowly and requires strict anaerobic conditions for cultivation. Much of the early phase of the research involved developing the genetic tools necessary to reliably program the bacteria to produce the therapeutic molecules at the right time and in the right amounts.
This research contributes to the burgeoning field known as "bugs as drugs," or live biotherapeutic products (LBPs). The microbiome has long been known to influence cancer treatment, but the move toward engineering specific microbes to perform tasks within the body represents the next frontier of precision medicine. By using a "generally recognized as safe" (GRAS) organism like Bifidobacterium, the researchers hope to streamline the path toward clinical application, as the safety profile of the base organism is already well-understood in humans.
Future Directions and Clinical Implications
While the results in animal models are promising, the researchers emphasize that BifidoSumIL-2 is still in the preclinical stage. Several hurdles remain before the therapy can be tested in human clinical trials. Future research will focus on the long-term safety of the engineered bacteria and whether the immune response it triggers can be sustained over time to prevent tumor recurrence.
One area of particular interest is the method of administration. In the current study, the bacteria were injected, but the team is investigating whether the therapy could eventually be delivered orally, similar to a standard probiotic supplement. If successful, this could provide a non-invasive way to maintain a therapeutic presence within the body. Additionally, the researchers plan to explore combinations with newer, more targeted therapies, such as KRAS inhibitors, which target the specific genetic mutations found in the vast majority of pancreatic cancers.
The timing of this research coincides with a major expansion of cancer care at the University of Chicago. In April 2027, UChicago Medicine is set to open the AbbVie Foundation Cancer Pavilion. As Chicago’s first freestanding facility dedicated entirely to cancer, the pavilion will be a hub for the kind of translational research exemplified by the BifidoSumIL-2 study, aiming to bring laboratory discoveries to the bedside more rapidly.
Conclusion
The development of BifidoSumIL-2 represents a sophisticated convergence of microbiology and oncology. By exploiting the very characteristics that make pancreatic tumors so difficult to treat—their low oxygen and isolated environment—scientists have found a way to deliver potent immune stimulants precisely where they are needed. While the road to a cure for pancreatic cancer remains long, the ability to transform a "cold" tumor into one that the immune system can see and attack provides a significant new lead in the fight against one of medicine’s most formidable challenges. The "bugs as drugs" approach offers a glimpse into a future where the treatments of tomorrow are grown as much as they are manufactured, providing hope for patients with few remaining options.
